Biocorrx (OTCMKTS:BICX – Get Free Report) announced its earnings results on Monday. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.02, Zacks reports.
Biocorrx Stock Performance
OTCMKTS:BICX opened at $0.21 on Monday. The stock has a 50-day simple moving average of $0.22 and a two-hundred day simple moving average of $0.31. Biocorrx has a 52-week low of $0.15 and a 52-week high of $1.28. The firm has a market capitalization of $6.47 million, a PE ratio of -1.76 and a beta of 0.07.
Biocorrx Company Profile
BioCorRx, Inc. is a healthcare company focused on substance-use-disorder treatment and related products. Its BioCorRx Recovery Program is an outpatient approach that combines medication-assisted treatment with counseling and ongoing support for people seeking treatment for alcohol or opioid dependence. The company has also pursued pharmaceutical products intended to support addiction treatment, including long-acting formulations. Its business includes developing treatment offerings and working to make them available through healthcare providers.
Featured Stories
- Five stocks we like better than Biocorrx
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Biocorrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocorrx and related companies with MarketBeat.com's FREE daily email newsletter.
